Diffuse large B-cell lymphoma refractory, also known as refractory DLBCL, describes a challenging situation where this aggressive form of blood cancer does not respond adequately to initial treatment, or when the response does not last very long. Understanding this condition and the available treatment approaches can help patients and their families navigate the difficult journey ahead.
Understanding Relapsed and Refractory Disease
When doctors talk about relapsed lymphoma, they are describing a situation where the disease comes back or begins to grow again after a period when it appeared to be under control, known as remission. This can happen weeks, months, or even years after the initial treatment seemed successful. The term refractory, on the other hand, is used to describe lymphoma that does not respond to treatment from the very beginning, meaning the cancer cells continue to grow despite therapy, or when any response to treatment is very brief and short-lived.[1]
These two situations—relapsed and refractory disease—often get discussed together because they present similar challenges for patients and doctors. Both represent cases where the standard first treatment approach has not worked as hoped, and new strategies must be considered. The difference between them mainly lies in timing: refractory disease never really responds to treatment in the first place, while relapsed disease initially responds but then returns.[5]
Epidemiology and Disease Burden
Diffuse large B-cell lymphoma is recognized as the most common type of aggressive non-Hodgkin lymphoma among adults. When patients receive standard first-line treatment with immunochemotherapy, approximately sixty to seventy percent can be cured. However, this means that roughly thirty to forty percent of patients will either experience disease that does not respond to treatment initially, or will see their lymphoma return after an initial response.[4][7]
Breaking down these numbers further, about fifteen to twenty percent of patients have disease that is refractory from the start, while another twenty to thirty percent will experience a relapse after achieving an initial response. Together, these patients represent a significant population facing poor outcomes and requiring more intensive treatment approaches.[6]
According to population-based studies conducted in the Netherlands, the real-world outcomes for patients with relapsed or refractory DLBCL confirm these concerning patterns. When examining contemporary clinical practice, researchers found that a significant proportion of patients who experience disease progression after first-line therapy face limited treatment options and poor survival outcomes, particularly if they are not eligible for intensive second-line therapies like stem cell transplantation.[8]
Causes and Development of Refractory Disease
Understanding why some cases of diffuse large B-cell lymphoma become refractory is complex and relates to the biological characteristics of the cancer cells themselves. DLBCL is not a single disease but rather represents a group of related cancers with significant biological differences. These differences mean that lymphoma cells in different patients may respond very differently to the same treatment approach.
The development of refractory disease is thought to be connected to the specific genetic and molecular features of the lymphoma cells. Some tumors have characteristics that make them naturally resistant to standard chemotherapy drugs. In other cases, the cancer cells may develop resistance mechanisms over time, which explains why a treatment that initially worked may eventually stop being effective.
The aggressive nature of diffuse large B-cell lymphoma itself contributes to the challenge. Because these cancer cells can grow and divide rapidly, there is often less time to adjust treatment strategies when the initial approach is not working. This rapid progression means that by the time doctors recognize that a treatment is not effective, the disease may have already advanced significantly.
Risk Factors for Poor Outcomes
Certain features and circumstances increase the likelihood that a patient will have refractory disease or experience particularly poor outcomes. The timing of disease progression or relapse plays a crucial role in predicting what will happen next. Patients whose disease never responds to initial treatment, or those who relapse within twelve months of starting therapy, face especially challenging situations. These patients are considered to be at the highest risk and typically require the most aggressive treatment approaches available.[4]
A patient’s overall physical condition and ability to tolerate intensive treatment also significantly impacts outcomes. Those who are elderly, have other serious medical conditions, or whose general health has been compromised by their cancer or its treatment may not be candidates for certain intensive therapies like stem cell transplantation. This limitation on treatment options can worsen the outlook for these patients.[6]
The extent and location of disease when relapse or progression is discovered matters as well. Patients with widespread disease, involvement of certain organs, or disease that has spread to the central nervous system may face additional treatment challenges. Similarly, certain laboratory test results, such as elevated levels of a substance called lactate dehydrogenase—an enzyme that can be higher in people with lymphoma—can signal more aggressive disease.[3]
Symptoms and Clinical Presentation
The symptoms experienced by patients with refractory or relapsed diffuse large B-cell lymphoma can vary considerably depending on where in the body the lymphoma is growing and how quickly it is progressing. Many patients notice swollen lymph nodes, which may appear as lumps in the neck, armpits, or groin areas. These swellings are typically painless but may grow rapidly.
Systemic symptoms—those affecting the whole body rather than just one area—are common and can be particularly troubling for patients. These include persistent fevers without an obvious infection, drenching night sweats that may require changing clothes or bedding, and unexplained weight loss. Feeling extremely tired or weak is also frequently reported and can significantly impact daily activities and quality of life.
When lymphoma affects specific organs, patients may experience symptoms related to those areas. For instance, if the disease involves the chest, patients might develop a persistent cough, shortness of breath, or chest discomfort. Lymphoma in the abdomen can cause pain, bloating, or changes in bowel habits. Some patients describe feeling generally unwell, similar to having flu-like symptoms that never fully go away, which can persist for extended periods before a diagnosis is confirmed.[10]
Diagnosis and Monitoring
Determining that DLBCL has become refractory or has relapsed requires careful evaluation through multiple types of tests. Doctors typically begin with a thorough physical examination to check for enlarged lymph nodes, an enlarged spleen, or other signs that the disease may be active. However, physical examination alone is not sufficient to confirm that lymphoma is present or growing.[3]
Blood tests play an important supporting role in the evaluation process. These tests can measure various markers that might suggest active lymphoma, including elevated lactate dehydrogenase levels. Blood tests may also check for viruses that can sometimes be associated with lymphoma, and they help doctors assess how well various organs are functioning, which is important for treatment planning.
Imaging tests are crucial for seeing where lymphoma is located in the body and measuring its extent. Several types of imaging may be used, including CT scans, which use X-rays to create detailed cross-sectional pictures of the body, and PET scans, which can detect metabolically active cancer cells. MRI may also be employed in certain situations. These imaging studies help doctors understand not just whether lymphoma is present, but also how much disease there is and where it is located.[3]
Perhaps most importantly, a biopsy—the removal of a sample of tissue for laboratory examination—is often recommended when relapse is suspected. This is because imaging tests can sometimes give misleading results, showing areas that look concerning but actually represent inflammation or scarring rather than active lymphoma. Additionally, a new biopsy allows doctors to examine the cancer cells under a microscope and perform specialized tests to understand their characteristics, which can help guide treatment decisions.[6]
Prevention Strategies
Unfortunately, once diffuse large B-cell lymphoma has been diagnosed, there are no proven strategies to prevent it from becoming refractory or relapsing. The development of refractory disease is related to the biological characteristics of the cancer cells themselves, rather than anything patients have done or failed to do. This is an important point because patients sometimes feel they are somehow to blame when treatment does not work, but the reality is that lymphoma behavior is largely beyond anyone’s control.
What patients can do is work closely with their healthcare team to ensure they receive appropriate initial treatment and careful monitoring afterward. Completing the full course of prescribed therapy, even when side effects are difficult, gives the best chance that treatment will be effective. Regular follow-up appointments after treatment ends are also essential, as they allow doctors to detect any signs of returning disease as early as possible, when it may be easier to treat.
Maintaining overall health through good nutrition, appropriate physical activity as tolerated, and avoiding infections when the immune system may be weakened can help patients tolerate treatment better. While these measures cannot prevent refractory disease, they may help patients remain strong enough to receive additional treatments if needed.
Treatment Approaches for Refractory Disease
The treatment of relapsed or refractory diffuse large B-cell lymphoma has evolved considerably in recent years, with several new options becoming available. The choice of treatment depends on multiple factors, including when the relapse occurred, whether the patient is healthy enough for intensive therapy, and what treatments have already been tried.
For patients who are physically fit enough to tolerate intensive treatment, high-dose chemotherapy followed by stem cell transplantation has historically been a standard approach. In an autologous transplant, doctors collect the patient’s own stem cells before administering very high doses of chemotherapy. These stem cells are then returned to the patient to help the bone marrow recover and start producing blood cells again. Occasionally, patients may receive stem cells from a donor in what is called an allogeneic transplant.[1][5]
Multiple second-line chemotherapy combinations are available for patients with relapsed or refractory disease. These include regimens with names like ICE, which combines ifosfamide, carboplatin, and etoposide, and DHAP, which uses dexamethasone, cisplatin, and cytarabine. Other options include gemcitabine-based therapy and the combination of bendamustine with rituximab. These combinations work differently from standard first-line treatment and may be effective even when initial therapy has failed.[1][5]
Several newer targeted therapies have been approved for relapsed or refractory DLBCL. These include drugs like polatuzumab vedotin-piiq, selinexor, tafasitamab-cxix, epcoritamab-bysp, and glofitamab-gxbm. The combination of lenalidomide with rituximab is another option. Each of these agents works through different mechanisms to attack lymphoma cells, and they represent important additions to the treatment landscape.[1][5]
For patients with a specific subtype of DLBCL called primary mediastinal large B-cell lymphoma who have relapsed or refractory disease, pembrolizumab is available as a treatment option. This drug works by helping the immune system recognize and attack cancer cells.[1]
The treatment landscape has become increasingly complex with all these options available, and doctors must carefully consider which approach is most appropriate for each individual patient. Factors influencing this decision include the timing of relapse, the patient’s ability to tolerate intensive treatment, previous treatments received, and the specific characteristics of the lymphoma cells. In recent years, there has been a major shift toward using CAR-T cell therapy earlier in the treatment course for certain high-risk patients, rather than waiting until multiple other treatments have failed.[4][7]
Pathophysiology and Disease Mechanisms
To understand why diffuse large B-cell lymphoma can be refractory to treatment, it helps to understand what happens at the cellular level. This disease originates from B-cells, which are a type of white blood cell normally responsible for producing antibodies to fight infections. In DLBCL, these B-cells undergo genetic changes that cause them to multiply uncontrollably and live longer than they should.
The reason some DLBCL cells are refractory to treatment relates to their internal machinery and the signals they use to survive and grow. Different lymphoma cells may have different genetic abnormalities and may rely on different pathways for survival. This biological diversity explains why a treatment that works well for one patient’s lymphoma may be completely ineffective for another patient’s disease, even though both technically have the same diagnosis.
When lymphoma cells become resistant to chemotherapy, they may develop various survival mechanisms. Some cancer cells become better at pumping chemotherapy drugs out before the drugs can do their damage. Others may develop ways to repair the DNA damage that chemotherapy causes, allowing them to survive despite treatment. Still others may find alternative growth pathways when one pathway is blocked by therapy.
The interaction between lymphoma cells and the surrounding normal tissues and immune cells also plays a role in refractory disease. Lymphoma cells can sometimes create an environment around themselves that protects them from both chemotherapy and the patient’s own immune system. They may recruit normal cells to support their growth or release substances that suppress immune responses against them.
Understanding these mechanisms has led to the development of many of the newer targeted therapies. Rather than using traditional chemotherapy that damages all rapidly dividing cells, these newer agents target specific vulnerabilities or pathways that lymphoma cells depend on for survival. This explains why some patients whose disease is refractory to standard chemotherapy may still respond to these novel targeted approaches.
